ArticleJournal of translational medicine2019

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.

Wenxian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.